摘要
目的:探讨益肾活血方联合硼替佐米治疗对多发性骨髓瘤肾损害患者胱抑素C(Cys C)、血视黄醇结合蛋白(RBP)、血β_(2)-微球蛋白(β_(2)-MG)、24 h尿蛋白定量的影响。方法:选取2019年5月-2020年5月广州市中西医结合医院收治的108例多发性骨髓瘤肾损害患者进行研究,采用随机数字表法将患者分为研究组(n=54)和对照组(n=54),对照组进行硼替佐米VD方案的药物治疗,研究组进行VD方案联合益肾活血方的药物治疗。分析两组患者的临床疗效、不良反应、Cys C、RBP、β_(2)-MG、24 h尿蛋白定量、骨代谢因子及免疫功能情况。结果:与对照组相比,研究组临床总有效率较高(P<0.05),不良反应发生率较低(P<0.05);与对照组相比,研究组治疗后Cys C、RBP、β_(2)-MG及24 h尿蛋白定量均较低(P<0.05);与对照组相比,研究组治疗后ALP及BGP水平均较高(P<0.05),CTX-Ⅰ水平较低(P<0.05);与对照组相比,研究组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)及Treg均较高(P<0.05)。结论:与单纯应用硼替佐米VD方案治疗相比,联合益肾活血方治疗对多发性骨髓瘤肾损害效果更为显著,可以有效改善患者骨代谢因子,提高免疫力,减少不良反应,具有较高的安全性,有利于促进其康复,值得大力推广。
Objective:To investigate the effects of Yishen Huoxue Decoction combined with Bortezomib on the quantification of cystatin C(Cys C),blood retinol binding protein(RBP),bloodβ_(2)-microglobulin(β_(2)-MG)and 24 h urinary protein in patients with multiple myeloma with renal damage.Method:A total of 108 patients with renal damage of multiple myeloma admitted to Guangzhou Integrated Chinese and Western Medicine Hospital from May 2019 to May 2020 were selected for this study,they were divided into study group(n=54)and control group(n=54)by random number table method.The control group received Bortezomib VD regimen,and the study group received VD regimen combined with Yishen Huoxue Decoction.Clinical efficacy,adverse reactions,Cys C,RBP,β_(2)-MG,24 h urinary protein,bone metabolic factors and immune function of the two groups were analyzed.Result:Compared with the control group,the total clinical effective rate was higher in the study group(P<0.05),and the incidence of adverse reactions was lower in the study group(P<0.05).Compared with the control group,the levels of Cys C,RBP,β_(2)-MG and 24 h urinary protein in the study group were lower after treatment(P<0.05).Compared with the control group,ALP and BGP levels were higher in the study group after treatment(P<0.05),while CTX-Ⅰlevel was lower in the study group(P<0.05).Compared with the control group,CD3^(+),CD4^(+),CD4^(+)/CD8^(+) and Treg were higher in the study group after treatment(P<0.05).Conclusion:Compared with the single application of Bortezomib VD regimen,the combined treatment of Yishen Huoxue Decoction has a more significant effect on renal damage of multiple myeloma,which can effectively improve the bone metabolism factors of patients,improve immunity,reduce adverse reactions,and has a high safety,which is conducive to promoting rehabilitation,and is worthy of promotion.
作者
李宜真
王栋范
李慧
LI Yizhen;WANG Dongfan;LI Hui(Guangzhou Integrated Chinese and Western Medicine Hospital,Guangzhou 510800,China;不详)
出处
《中国医学创新》
CAS
2022年第2期52-56,共5页
Medical Innovation of China
